Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
ConditionIndolent B-Cell Non-Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age20-100
SponsorKoo Foundation Sun Yat-Sen Cancer Center
About this trial
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Eligibility criteria
Qualifiers
The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma.
Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group.
Able to lie flat for at least 30 minutes.
Signing the subject consent form.
Disqualifiers
Pregnant woman
Severe renal impairment (eGRF< 30ml/min)
Known or suspected allergy to radiopharmaceuticals
Concurrent or previous diagnosis of malignancies other than lymphoma
Trial design
Treatments tested in this trial
- Ga-68-CXCR4
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov